EUVIMEDEUVIMED entdecken
Leserbrief

STING-Associated Vasculopathy with Onset in infancy (SAVI) Presenting as Massive Intra Alveolar Hemorrhage

Clara Ladoux, Marlène Pasquet, Yanick J Crow, Marie Louise Frémond, Léa Roditis

Journal of Clinical Immunology · 2023-05 · 43 (4) · 699-702

DOI: 10.1007/s10875-023-01431-9 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Immunology, online erschienen am 17.01.2023. Verfasst von Clara Ladoux und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, Pediatric Residency, University of Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Vascular Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type I interferons (IFNs) play a critical role in the innate immune response to pathogens, and abnormal activation of IFN signaling underlies a group of autoinflammatory diseases referred to as the type I interferonopathies. Stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) is a monogenic type I interferonopathy first described in 2014, caused by gain-of-function mutations in STING1 (previously named TMEM173) encoding STING, a key adaptor of the DNA recognition pathway [1]. Constitutive activation of STING triggers systemic inflammation, most typically resulting in skin damage (purplish scaly lesions of the extremities exacerbated by cold), pulmonary disease (recurrent cough, interstitial lung disease), and polyarthritis. Laboratory indices can be consistent with multisystem inflammation, with anemia, thrombocytosis, and elevated CRP. Non-specific markers of autoimmunity can also be positive [1]. SAVI-associated pulmonary involvement presents as diffuse interstitial lung disease that progresses to fibrosis. It is present in most patients, with, or in the absence of, other disease features [2]. Of note, to date, no case of SAVI manifesting as life threatening intra-alveolar hemorrhage has been described. Studies are in favor of a promising effect of JAK 1/2 inhibitors [2, 3] on all aspects of the SAVI clinical phenotype. Data suggest that baricitinib improves disease signs and symptoms and allows for a reduction of corticosteroid treatment. Here we describe a female child diagnosed with SAVI at the age of 4 years after an episode of severe diffuse alveolar hemorrhage, successfully treated with the JAK 1/2 inhibitor baricitinib and corticosteroids. She is the first child of an unrelated healthy couple. She had been followed from the age of 2.5 years for severe chronic anemia (lowest hemoglobin (Hb) 3 g/dl) attributed to iron deficiency after extensive investigation. She also had a diagnosis of reactive airway disease because of chronic dry cough exacerbated during viral infections treated with inhaled steroids. Growth was impaired, height being one standard deviation (SD) below her target height, and body mass index (BMI) in the third percentile. At the age of 3.5 years she presented with life-threatening acute respiratory distress requiring admission to an intensive care unit. Tests showed a poorly regenerative microcytic anemia (Hb 6.4 g/dL, mean corpuscular volume (MCV) 64 fl, reticulocytes 95 G/L [25–100 G/L]) without involvement of other lineages. Hemolytic anemia was ruled out. High resolution CT scan (HRCT) showed patchy alveolar condensation with ground glass opacities, and some centrilobular emphysema images (Fig. 1, B1). Bronchoscopy revealed profuse macroscopic intra-bronchial bleeding. Bronchoalveolar lavage (BAL) fluid analysis was noncontributory due to high contamination with bronchial cells. Extensive testing was negative, including basic immunologic tests of B and T cell function, microbiological exploration of sputum (bacterial, viral, fungal, and parasite) and research for cow’s milk allergy, and coeliac disease. Antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA), anti-double stranded DNA antibodies (anti DNA), rheumatoid factor (FR), and anti-glomerular basement membrane (anti GBM) were all negative. Of note, no lung biopsy * Léa Roditis roditis.l@chu-toulouse.fr

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular DiseasesHumansInfantHemorrhageInflammationSTING Protein

Substanzen

STING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • Medical School, Pediatric Residency, University of Toulouse, Toulouse, France.
  • Department of Pediatric Hematology and Immunology, Children's Hospital, University Hospital, Toulouse, France.
  • Inserm UMR 1163, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, Université Paris Cité, Paris, France.
  • MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Pediatric Haematology-Immunology and Rheumatology Unit, Necker Hospital, AP-HP.Centre - Université Paris Cité, Paris, France.
  • Department of Pediatric Pulmonology and Allergology, Children's Hospital, University Hospital, Toulouse, France. roditis.l@chu-toulouse.fr.

Zitieren

APA

Ladoux, C., Pasquet, M., Crow, Y. J., Frémond, M. L., & Roditis, L. (2023). STING-Associated Vasculopathy with Onset in infancy (SAVI) Presenting as Massive Intra Alveolar Hemorrhage. Journal of Clinical Immunology, 43(4), 699-702. https://doi.org/10.1007/s10875-023-01431-9

Vancouver

Ladoux C, Pasquet M, Crow YJ, Frémond ML, Roditis L. STING-Associated Vasculopathy with Onset in infancy (SAVI) Presenting as Massive Intra Alveolar Hemorrhage. Journal of Clinical Immunology. 2023;43(4):699-702. doi:10.1007/s10875-023-01431-9

BibTeX
@article{Ladoux2023,
  author = {Ladoux, Clara and Pasquet, Marlène and Crow, Yanick J and Frémond, Marie Louise and Roditis, Léa},
  title = {STING-Associated Vasculopathy with Onset in infancy (SAVI) Presenting as Massive Intra Alveolar Hemorrhage},
  journal = {Journal of Clinical Immunology},
  year = {2023},
  volume = {43},
  number = {4},
  pages = {699--702},
  doi = {10.1007/s10875-023-01431-9}
}
Kostenlos starten →